microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13

被引:23
作者
Han, Han [1 ]
Chen, Yuxing [1 ]
Cheng, Li [1 ]
Prochownik, Edward V. [2 ,3 ]
Li, Youjun [1 ]
机构
[1] Wuhan Univ, Coll Life Sci, Med Res Inst, Wuhan 430072, Peoples R China
[2] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh UPMC, Div Hematol Oncol, Pittsburgh, PA 15224 USA
[3] Univ Pittsburgh, Med Ctr, Dept Microbiol & Mol Genet, Pittsburgh, PA 15224 USA
基金
中国国家自然科学基金;
关键词
Myc; microRNA; MAP3K13; breast cancer; NEGATIVE BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGETS; CELL-CYCLE; TUMORIGENESIS; PATHWAY; TRANSCRIPTION; ACTIVATION; EXPRESSION; GROWTH;
D O I
10.18632/oncotarget.7653
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
c-Myc (Myc) is one of the most frequently dysregulated oncogenic transcription factors in human cancer. By functionally screening a microRNA (miR) library, we identified miR-206 as being a synthetic lethal in Myc over-expressing human cancer cells. miR-206 inhibited MAP3K13, which resulted in Myc protein de-stabilization, and an inhibition of anchorage-independent growth and in vivo tumorigenesis by Myc over-expressing human cancer cells. Eliminating MAP3K13 by shRNA recapitulated the effects caused by miR-206, thus supporting the idea that miR-206's effect on Myc was mediated through MAP3K13. Conversely, enforced expression of MAP3K13 stabilized Myc by promoting its N-terminal phosphorylation and enhancing its transcriptional activity. Gene expression analyses of breast cancers expressing high levels of Myc indicated that low miR-206 expression and high MAP3K13 expression correlated with poor patient survival. The critical link between miR-206 and MAP3K13 in the development of Myc over-expressing human cancers suggests potential points of therapeutic intervention for this molecular sub-category.
引用
收藏
页码:16409 / 16419
页数:11
相关论文
共 48 条
[1]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[2]   Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis [J].
Bosch, Almudena ;
Bertran, Silvina P. ;
Lu, Yongke ;
Garcia, Avalon ;
Jones, Alexis M. ;
Dawson, Marcia I. ;
Farias, Eduardo F. .
BREAST CANCER RESEARCH, 2012, 14 (04)
[3]   MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[4]   Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue [J].
Chrzan, P ;
Skokowski, J ;
Karmolinski, A ;
Pawelczyk, T .
CLINICAL BIOCHEMISTRY, 2001, 34 (07) :557-562
[5]   A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions [J].
Creighton, Chad J. ;
Nagaraja, Ankur K. ;
Hanash, Samir M. ;
Matzuk, Martin M. ;
Gunaratne, Preethi H. .
RNA, 2008, 14 (11) :2290-2296
[6]   MYC on the Path to Cancer [J].
Dang, Chi V. .
CELL, 2012, 149 (01) :22-35
[7]   Myc's broad reach [J].
Eilers, Martin ;
Eisenman, Robert N. .
GENES & DEVELOPMENT, 2008, 22 (20) :2755-2766
[8]   Small-molecule inhibitors of the Myc oncoprotein [J].
Fletcher, Steven ;
Prochownik, Edward V. .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2015, 1849 (05) :525-543
[9]   Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC [J].
Goga, Andrei ;
Yang, Dun ;
Tward, Aaron D. ;
Morgan, David O. ;
Bishop, J. Michael .
NATURE MEDICINE, 2007, 13 (07) :820-827
[10]   Direct activation of RNA polymerase III transcription by c-Myc [J].
Gomez-Roman, N ;
Grandori, C ;
Eisenman, RN ;
White, RJ .
NATURE, 2003, 421 (6920) :290-294